Alastair Greystoke, MBChB, MSc, PhD, MRCP, Northern Institute for Cancer Research, Newcastle University, Newcastle, UK, outlines a paper he recently co-authored regarding systemic treatment following immunotherapy. The study aimed to assess whether patients were remaining on immunotherapy for too long, and hence not healthy enough to progress onto further treatment regimens. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

свернуть